Acquisition by David Snyder of 115000 shares of Coya Therapeutics, at 3.85 subject to Rule 16b-3
COYA Stock | 6.52 0.13 1.95% |
About 54% of Coya Therapeutics,'s investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Coya Therapeutics, Common suggests that some traders are interested. The current market sentiment, together with Coya Therapeutics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Coya Therapeutics, Common stock news signals to limit their universe of possible portfolio assets.
Coya |
Filed transaction by Coya Therapeutics, Common Officer: Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at thelincolnianonline.com
Coya Therapeutics, Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Coya Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Coya Therapeutics, Fundamental Analysis
We analyze Coya Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coya Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coya Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Coya Therapeutics, is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Coya Therapeutics, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Coya Therapeutics, stock to make a market-neutral strategy. Peer analysis of Coya Therapeutics, could also be used in its relative valuation, which is a method of valuing Coya Therapeutics, by comparing valuation metrics with similar companies.
Peers
Coya Therapeutics, Related Equities
CUE | Cue Biopharma | 11.93 | ||||
OPT | Opthea | 10.81 | ||||
TFFP | Tff Pharmaceuticals | 9.68 | ||||
GANX | Gain Therapeutics | 6.90 | ||||
LTRN | Lantern Pharma | 3.22 | ||||
TCRX | Tscan Therapeutics | 2.80 | ||||
DRMA | Dermata Therapeutics | 2.73 | ||||
CNTA | Centessa Pharmaceuticals | 1.76 | ||||
DAWN | Day One | 1.53 | ||||
FENC | Fennec Pharmaceuticals | 0.83 | ||||
HLVX | Hillevax | 0.52 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
STRO | Sutro Biopharma | 1.49 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
CGTX | Cognition Therapeutics | 2.44 | ||||
INAB | In8bio | 3.23 | ||||
NAMSW | NewAmsterdam Pharma | 6.50 |
Complementary Tools for Coya Stock analysis
When running Coya Therapeutics,'s price analysis, check to measure Coya Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coya Therapeutics, is operating at the current time. Most of Coya Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Coya Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coya Therapeutics,'s price. Additionally, you may evaluate how the addition of Coya Therapeutics, to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |